Outlook on the Cryptococcosis Treatment Global Market to 2026 - Drug Development and Evolving Clinical Trial Ecosystem Presents Opportunities

Dublin, June 25, 2021 (GLOBE NEWSWIRE) -- The "Global Cryptococcosis Treatment Market (2021-2026) byTreatment, Distribution Channel, Geography and the Impact of COVID-19 with Ansoff Analysis" report has been added to ResearchAndMarkets.com's offering.

Cryptococcosis or cryptococcal disease is basically a fungal disease, which can prove to be fatal in severe cases. It occurs due to inhalation of fungus associated with bird species. It can affect the humans leading to meningitis in several cases. The occurrence of this disease is increasing beyond years due to the rise in the number of diseases especially prevalent in the emerging economies.

Certain infections like HIV which lead to a weak immune system as well as the extended use of immunosuppressive drugs are supporting the growth of this market. Alternatively, lack of efficient diagnostic tools and trials to prevent this infection are digressing the growth of this market.

The Global Cryptococcosis Treatment Market is estimated to be USD 4.8 Bn in 2021 and is expected to reach USD 6 Bn by 2026 growing at a CAGR of 4.5%.

Market Dynamics

Drivers

• The growing incidence of cryptococcosis infections
• Increasing incidence of fatal fungal infections
• Increasing availability of generic and over-the-counter (OTC) medicines

Restraints

• Reduced scope of testing and diagnostics due to increased mortality among cryptococcosis infected patients
• Limited clinical awareness in patients
• Lack of skilled technicians

Opportunities

• Drug development and evolving clinical trial ecosystem
• Initiatives undertaken by the government, NGOs, and the healthcare providers

Segments Covered

By Geography, North America leads the market. The Global Cryptococcossis market can be segmented on the basis of treatment, distribution channel and geography.

Global Cryptococcosis Treatment Market, By Treatment

• Introduction
• Amphotericin B
• Amphocin
• Fungizone
• Others
• Fluconazole
• Diflucan
• Others
• Flucytosine
• Ancobon
• Others
• Others (Voriconazole, Surgery Treatment, etc.)

Global Cryptococcosis Treatment Market, By Distribution Channel

• Introduction
• Hospital Pharmacies
• Mail Order Pharmacies
• Retail Pharmacies & Drug Stores

Global Cryptococcosis Treatment Market, By Geography

• North America
• South America
• Europe
• Asia Pacific
• Middle East and Africa

Company Profiles

Some of the companies covered in this report are Glenmark Pharmaceuticals, Abbott , Pfizer , Bristol-Mayers Squibb, Sigmapharm Laboratories, Novartis AG etc.

Competitive Quadrant

The report includes a Competitive Quadrant, a proprietary tool to analyze and evaluate the position of companies based on their Industry Position score and Market Performance score. The tool uses various factors for categorizing the players into four categories. Some of these factors considered for analysis are financial performance over the last 3 years, growth strategies, innovation score, new product launches, investments, growth in market share etc.

Why buy this report?

• The report offers a comprehensive evaluation of the Global Cryptococcosis Market.
• The report includes in-depth qualitative analysis, verifiable data from authentic sources and projections about market size. The projections are calculated using proven research methodologies.
• The report has been compiled through extensive primary and secondary research. The primary research is done through interviews, surveys and observation of renowned personnel in the industry.
• The report includes in-depth market analysis using Porter's 5 force model and the Ansoff Matrix. The impact of Covid-19 on the market is also featured in the report.
• The report also contains the competitive analysis using Competitive Quadrant, the analyst's proprietary competitive positioning tool.

Report Highlights:

• A complete analysis of the market including parent industry
• Important market dynamics and trends
• Market segmentation
• Historical, current, and projected size of the market based on value and volume
• Market shares and strategies of key players
• Recommendations to companies for strengthening their foothold in the market

Key Topics Covered:

1 Report Description

2 Research Methodology

3 Executive Summary

4 Market Overview
4.1 Introduction
4.2 Market Dynamics
4.2.1 Drivers
4.2.2 Restraints
4.2.3 Opportunities
4.3 Trends

5 Market Analysis
5.1 Porter's Five Forces Analysis
5.2 Impact of COVID-19
5.3 Ansoff Matrix Analysis

6 Global Cryptococcosis Treatment Market, By Treatment
6.1 Introduction
6.2 Amphotericin B
6.2.1 Amphocin
6.2.2 Fungizone
6.2.3 Others
6.3 Fluconazole
6.3.1 Diflucan
6.3.2 Others
6.4 Flucytosine
6.4.1 Ancobon
6.4.2 Others
6.5 Others (Voriconazole, Surgery Treatment, etc.)

7 Global Cryptococcosis Treatment Market, By Distribution Channel
7.1 Introduction
7.2 Hospital Pharmacies
7.3 Mail Order Pharmacies
7.4 Retail Pharmacies & Drug Stores

8 Global Cryptococcosis Treatment Market, By Geography
8.1 Introduction
8.2 North America
8.2.1 US
8.2.2 Canada
8.2.3 Mexico
8.3 South America
8.3.1 Brazil
8.3.2 Argentina
8.4 Europe
8.4.1 UK
8.4.2 France
8.4.3 Germany
8.4.4 Italy
8.4.5 Rest of Europe
8.5 Asia-Pacific
8.5.1 China
8.5.2 Japan
8.5.3 India
8.5.4 Australia
8.5.5 Rest of APAC
8.6 Middle East and Africa

9 Competitive Landscape
9.1 Competitive Quadrant
9.2 Market Share Analysis
9.3 Competitive Scenario
9.3.1 Mergers & Acquisitions
9.3.2 Agreements, Collaborations, & Partnerships
9.3.3 New Product Launches & Enhancements
9.3.4 Investments & Fundings

10 Company Profiles
10.1 Bristol-Myers Squibb Company
10.2 Janssen Biotech, Inc. ( Johnson & Johnson )
10.3 Abbott
10.4 Novartis AG
10.5 Pfizer , Inc.
10.6 Valeant Pharmaceuticals, Inc.
10.7 Glenmark Pharmaceuticals
10.8 Viamet Pharmaceuticals, Inc.
10.9 Sigmapharm Laboratories LLC
10.10 Astellas Pharma Inc.
10.11 Bausch Health Companies Inc.
10.12 Matinas BioPharma
10.13 NuCare Pharmaceuticals, Inc.
10.14 Teva Pharmaceutical Industries Ltd.

11 Appendix

For more information about this report visit https://www.researchandmarkets.com/r/6qk8sb

CONTACT: CONTACT: ResearchAndMarkets.com
         Laura Wood,  Senior  Press Manager
         press@researchandmarkets.com
         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900